{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-24-000012","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.139636+00:00","generated_at":"2026-06-05T14:55:05.253013+00:00","sec_items":["1.01","2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"iBio sells PD-1 agonist program to Otsuka for $1M upfront; up to $52.5M milestones","bullets":["Otsuka acquired iBio's PD-1 agonist assets; $1M cash at closing, up to $52.5M in development and commercial milestones.","iBio originally acquired the PD-1 assets from RubrYc Therapeutics in September 2022; no related milestone obligations.","Deal closes Feb 25, 2024; iBio will redirect resources to its proprietary immuno-oncology pipeline and AI platform.","PD-1 agonists target autoimmune diseases; CEO Martin Brenner calls transaction a win-win and non-dilutive capital source."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-24-000012","json":"https://secwatch.observer/filing/0001420720-24-000012.json","markdown":"https://secwatch.observer/filing/0001420720-24-000012.md","text":"https://secwatch.observer/filing/0001420720-24-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000012/0001420720-24-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000012/ibio-20240226x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T14:55:05.253013+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6367b8e78a7d1e8345b482d346012726fc986bb4","claim":"iBio, Inc. completed a disposition involving Otsuka Pharmaceutical Co., Ltd. for $1,000,000 paid at closing (closed 2024-02-25).","evidence_excerpt":"and assumed, all intellectual property rights directly related to the Company’s PD-1 agonist assets (the “PD-1 Assets”) developed or held for development in consideration of $1,000,000 paid at closing (the “Closing Consideration”). The Purchase Agreement also provides for a potential contingent payment of $2,500,000 upon the achievement of specified","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000012/0001420720-24-000012-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Otsuka Pharmaceutical Co., Ltd."},{"label":"Consideration","value":"$1,000,000 paid at closing"},{"label":"Closing","value":"2024-02-25"}],"fact_type":"ma_transaction"},{"claim_id":"9d5e3c37df13822a0d87e5f0af076efcb2576b35","claim":"iBio, Inc. entered into Asset Purchase Agreement with Otsuka Pharmaceutical Co., Ltd. valued at $1,000,000 paid at closing (effective 2024-02-25).","evidence_excerpt":"On February 25, 2024, iBio, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Otsuka Pharmaceutical Co., Ltd. (“Otsuka”) pursuant to which the Company sold and assigned to Otsuka, and Otsuka purchased and assumed, all intellectual property rights directly related to the Company’s PD-1 agonist assets (the “PD-1 Assets”) developed or held for development in consideration of $1,000,000 paid at closing (the “Closing Consideration”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000012/0001420720-24-000012-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Otsuka Pharmaceutical Co., Ltd."},{"label":"Value","value":"$1,000,000 paid at closing"},{"label":"Effective","value":"2024-02-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}